Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer
Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ziemba, Barbara [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides - Nigolian, H. ELSEVIER, 2022, New York, NY [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:461 ; year:2014 ; number:1 ; day:30 ; month:01 ; pages:391-402 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijpharm.2013.12.011 |
|---|
| Katalog-ID: |
ELV028132629 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV028132629 | ||
| 003 | DE-627 | ||
| 005 | 20230625153155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2013.12.011 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014012000003.pica |
| 035 | |a (DE-627)ELV028132629 | ||
| 035 | |a (ELSEVIER)S0378-5173(13)01079-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.61 |2 bkl | ||
| 100 | 1 | |a Ziemba, Barbara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. | ||
| 520 | |a Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. | ||
| 650 | 7 | |a Dendrimer |2 Elsevier | |
| 650 | 7 | |a Toxicity |2 Elsevier | |
| 650 | 7 | |a PPI |2 Elsevier | |
| 650 | 7 | |a Glycodendrimer |2 Elsevier | |
| 650 | 7 | |a Proliferation |2 Elsevier | |
| 650 | 7 | |a Apoptosis |2 Elsevier | |
| 700 | 1 | |a Franiak-Pietryga, Ida |4 oth | |
| 700 | 1 | |a Pion, Marjorie |4 oth | |
| 700 | 1 | |a Appelhans, Dietmar |4 oth | |
| 700 | 1 | |a Muñoz-Fernández, Maria Ángeles |4 oth | |
| 700 | 1 | |a Voit, Brigitte |4 oth | |
| 700 | 1 | |a Bryszewska, Maria |4 oth | |
| 700 | 1 | |a Klajnert-Maculewicz, Barbara |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Nigolian, H. ELSEVIER |t Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |d 2022 |g New York, NY [u.a.] |w (DE-627)ELV008932840 |
| 773 | 1 | 8 | |g volume:461 |g year:2014 |g number:1 |g day:30 |g month:01 |g pages:391-402 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijpharm.2013.12.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.61 |j Innere Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 461 |j 2014 |e 1 |b 30 |c 0130 |h 391-402 |g 12 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
b z bz |
|---|---|
| matchkey_str |
ziembabarbarafraniakpietrygaidapionmarjo:2014----:oiiynpoppoiatvtoplpoyeemngyoediesnircnieighicnrrptnilsi |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
44.61 |
| publishDate |
2014 |
| allfields |
10.1016/j.ijpharm.2013.12.011 doi GBVA2014012000003.pica (DE-627)ELV028132629 (ELSEVIER)S0378-5173(13)01079-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ziemba, Barbara verfasserin aut Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis Elsevier Franiak-Pietryga, Ida oth Pion, Marjorie oth Appelhans, Dietmar oth Muñoz-Fernández, Maria Ángeles oth Voit, Brigitte oth Bryszewska, Maria oth Klajnert-Maculewicz, Barbara oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:461 year:2014 number:1 day:30 month:01 pages:391-402 extent:12 https://doi.org/10.1016/j.ijpharm.2013.12.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 461 2014 1 30 0130 391-402 12 045F 610 |
| spelling |
10.1016/j.ijpharm.2013.12.011 doi GBVA2014012000003.pica (DE-627)ELV028132629 (ELSEVIER)S0378-5173(13)01079-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ziemba, Barbara verfasserin aut Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis Elsevier Franiak-Pietryga, Ida oth Pion, Marjorie oth Appelhans, Dietmar oth Muñoz-Fernández, Maria Ángeles oth Voit, Brigitte oth Bryszewska, Maria oth Klajnert-Maculewicz, Barbara oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:461 year:2014 number:1 day:30 month:01 pages:391-402 extent:12 https://doi.org/10.1016/j.ijpharm.2013.12.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 461 2014 1 30 0130 391-402 12 045F 610 |
| allfields_unstemmed |
10.1016/j.ijpharm.2013.12.011 doi GBVA2014012000003.pica (DE-627)ELV028132629 (ELSEVIER)S0378-5173(13)01079-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ziemba, Barbara verfasserin aut Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis Elsevier Franiak-Pietryga, Ida oth Pion, Marjorie oth Appelhans, Dietmar oth Muñoz-Fernández, Maria Ángeles oth Voit, Brigitte oth Bryszewska, Maria oth Klajnert-Maculewicz, Barbara oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:461 year:2014 number:1 day:30 month:01 pages:391-402 extent:12 https://doi.org/10.1016/j.ijpharm.2013.12.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 461 2014 1 30 0130 391-402 12 045F 610 |
| allfieldsGer |
10.1016/j.ijpharm.2013.12.011 doi GBVA2014012000003.pica (DE-627)ELV028132629 (ELSEVIER)S0378-5173(13)01079-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ziemba, Barbara verfasserin aut Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis Elsevier Franiak-Pietryga, Ida oth Pion, Marjorie oth Appelhans, Dietmar oth Muñoz-Fernández, Maria Ángeles oth Voit, Brigitte oth Bryszewska, Maria oth Klajnert-Maculewicz, Barbara oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:461 year:2014 number:1 day:30 month:01 pages:391-402 extent:12 https://doi.org/10.1016/j.ijpharm.2013.12.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 461 2014 1 30 0130 391-402 12 045F 610 |
| allfieldsSound |
10.1016/j.ijpharm.2013.12.011 doi GBVA2014012000003.pica (DE-627)ELV028132629 (ELSEVIER)S0378-5173(13)01079-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ziemba, Barbara verfasserin aut Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis Elsevier Franiak-Pietryga, Ida oth Pion, Marjorie oth Appelhans, Dietmar oth Muñoz-Fernández, Maria Ángeles oth Voit, Brigitte oth Bryszewska, Maria oth Klajnert-Maculewicz, Barbara oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:461 year:2014 number:1 day:30 month:01 pages:391-402 extent:12 https://doi.org/10.1016/j.ijpharm.2013.12.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 461 2014 1 30 0130 391-402 12 045F 610 |
| language |
English |
| source |
Enthalten in Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides New York, NY [u.a.] volume:461 year:2014 number:1 day:30 month:01 pages:391-402 extent:12 |
| sourceStr |
Enthalten in Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides New York, NY [u.a.] volume:461 year:2014 number:1 day:30 month:01 pages:391-402 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Innere Medizin |
| institution |
findex.gbv.de |
| topic_facet |
Dendrimer Toxicity PPI Glycodendrimer Proliferation Apoptosis |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| authorswithroles_txt_mv |
Ziemba, Barbara @@aut@@ Franiak-Pietryga, Ida @@oth@@ Pion, Marjorie @@oth@@ Appelhans, Dietmar @@oth@@ Muñoz-Fernández, Maria Ángeles @@oth@@ Voit, Brigitte @@oth@@ Bryszewska, Maria @@oth@@ Klajnert-Maculewicz, Barbara @@oth@@ |
| publishDateDaySort_date |
2014-01-30T00:00:00Z |
| hierarchy_top_id |
ELV008932840 |
| dewey-sort |
3610 |
| id |
ELV028132629 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV028132629</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625153155.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijpharm.2013.12.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014012000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV028132629</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5173(13)01079-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ziemba, Barbara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dendrimer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PPI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glycodendrimer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Proliferation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Apoptosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franiak-Pietryga, Ida</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pion, Marjorie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Appelhans, Dietmar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muñoz-Fernández, Maria Ángeles</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Voit, Brigitte</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bryszewska, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klajnert-Maculewicz, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nigolian, H. ELSEVIER</subfield><subfield code="t">Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides</subfield><subfield code="d">2022</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008932840</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:461</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">day:30</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:391-402</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijpharm.2013.12.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">461</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="b">30</subfield><subfield code="c">0130</subfield><subfield code="h">391-402</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Ziemba, Barbara |
| spellingShingle |
Ziemba, Barbara ddc 610 bkl 44.61 Elsevier Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer |
| authorStr |
Ziemba, Barbara |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008932840 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.61 bkl Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis Elsevier |
| topic |
ddc 610 bkl 44.61 Elsevier Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis |
| topic_unstemmed |
ddc 610 bkl 44.61 Elsevier Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis |
| topic_browse |
ddc 610 bkl 44.61 Elsevier Dendrimer Elsevier Toxicity Elsevier PPI Elsevier Glycodendrimer Elsevier Proliferation Elsevier Apoptosis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
i f p ifp m p mp d a da m á m f mám mámf b v bv m b mb b k m bkm |
| hierarchy_parent_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| hierarchy_parent_id |
ELV008932840 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008932840 |
| title |
Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer |
| ctrlnum |
(DE-627)ELV028132629 (ELSEVIER)S0378-5173(13)01079-X |
| title_full |
Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer |
| author_sort |
Ziemba, Barbara |
| journal |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| journalStr |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
391 |
| author_browse |
Ziemba, Barbara |
| container_volume |
461 |
| physical |
12 |
| class |
610 610 DE-600 610 VZ 44.61 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ziemba, Barbara |
| doi_str_mv |
10.1016/j.ijpharm.2013.12.011 |
| dewey-full |
610 |
| title_sort |
toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer |
| title_auth |
Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer |
| abstract |
Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. |
| abstractGer |
Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. |
| abstract_unstemmed |
Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
1 |
| title_short |
Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer |
| url |
https://doi.org/10.1016/j.ijpharm.2013.12.011 |
| remote_bool |
true |
| author2 |
Franiak-Pietryga, Ida Pion, Marjorie Appelhans, Dietmar Muñoz-Fernández, Maria Ángeles Voit, Brigitte Bryszewska, Maria Klajnert-Maculewicz, Barbara |
| author2Str |
Franiak-Pietryga, Ida Pion, Marjorie Appelhans, Dietmar Muñoz-Fernández, Maria Ángeles Voit, Brigitte Bryszewska, Maria Klajnert-Maculewicz, Barbara |
| ppnlink |
ELV008932840 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ijpharm.2013.12.011 |
| up_date |
2024-07-06T18:01:33.679Z |
| _version_ |
1803853646979399680 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV028132629</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625153155.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijpharm.2013.12.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014012000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV028132629</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5173(13)01079-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ziemba, Barbara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers’ desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) – for full (dense shell – DS) or partial (open shell – OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dendrimer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PPI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glycodendrimer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Proliferation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Apoptosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franiak-Pietryga, Ida</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pion, Marjorie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Appelhans, Dietmar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muñoz-Fernández, Maria Ángeles</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Voit, Brigitte</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bryszewska, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klajnert-Maculewicz, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nigolian, H. ELSEVIER</subfield><subfield code="t">Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides</subfield><subfield code="d">2022</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008932840</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:461</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">day:30</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:391-402</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijpharm.2013.12.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">461</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="b">30</subfield><subfield code="c">0130</subfield><subfield code="h">391-402</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4002686 |